Clinical trials
Lung Neoplasms trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 4 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 6 |
| Active, not recruiting | 6 |
| Terminated | 3 |
| Not yet recruiting | 3 |
| Unknown status | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Novartis Pharmaceuticals | 5 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 5 |
| Pfizer | 4 |
| Bristol-Myers Squibb | 3 |
| Eli Lilly and Company | 3 |
| All India Institute of Medical Sciences | 2 |
| Genzyme, a Sanofi Company | 2 |
| Peregrine Pharmaceuticals | 2 |
| Tata Memorial Hospital | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 46 |
| Carcinoma, Non-Small-Cell Lung | 25 |
| Carcinoma | 5 |
| Neoplasm Metastasis | 4 |
| Small Cell Lung Carcinoma | 3 |
| Adenocarcinoma of Lung | 2 |
| Bronchial Neoplasms | 2 |
| Lung Diseases | 2 |
| Neoplasms | 2 |
| Pleural Effusion | 2 |
Trials
Showing 26 to 46 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.